QURE.AI: REVOLUTIONIZING HEALTHCARE THROUGH AI-POWERED MEDICAL IMAGING IN INDIA
1. Introduction
The healthcare landscape of India, a nation of over 1.4 billion people, presents a dichotomy of world-class medical innovation and profound accessibility gaps. While metropolitan hubs boast state-of-the-art hospitals, the vast hinterlands struggle with a severe shortage of medical infrastructure and specialists. A critical bottleneck in this ecosystem is diagnostic radiology. India faces a staggering shortage of radiologists, with estimates suggesting there is only one radiologist for every 100,000 people, compared to significantly higher ratios in developed nations. This scarcity leads to delayed diagnoses, misinterpretation of scans in rural centers, and ultimately, preventable morbidity and mortality.
In this challenging environment, Artificial Intelligence (AI) has emerged not merely as a technological novelty but as a necessary bridge to equitable healthcare. At the forefront of this revolution is Qure.ai, an Indian health-tech startup founded in Mumbai in 2016. Born out of the necessity to democratize access to high-quality diagnostics, Qure.ai leverages deep learning technology to interpret medical images such as X-rays, CT scans, and ultrasounds. Its mission is clear: to make healthcare accessible and affordable by automating diagnostic interpretation, thereby empowering clinicians and health workers to make faster, more accurate decisions.
Qure.ai’s journey from a Mumbai-based startup to a global leader in medical imaging AI is a testament to the quality of Indian innovation. Today, its solutions are deployed in over 100 countries across more than 3,000 healthcare sites. However, its impact is most profoundly felt in its home country, India, where it supports government tuberculosis elimination programs, enhances stroke care in tier-2 cities, and assists in lung cancer screening. By integrating AI into the workflow of public health centers and private hospitals alike, Qure.ai is addressing the “iron triangle” of healthcare—access, cost, and quality—simultaneously.
This article provides a comprehensive analysis of Qure.ai’s operations within India. It explores the technology behind their FDA-cleared algorithms, details specific hospital partnerships such as those with Medanta and Aster MIMS, and examines real-world case studies of patients whose lives were saved through timely AI intervention. As India marches towards its digital health mission, Qure.ai stands as a beacon of how technology can be harnessed to heal a nation.
2. Company Background
Founded in 2016, Qure.ai was established by Prashant Warier and Pooja Rao, two visionaries who recognized the potential of artificial intelligence to solve the scalability issues in radiology. Headquartered in Mumbai, the company began with a focus on chest X-rays and head CT scans, the two most common yet critical diagnostic modalities. Prashant Warier, serving as CEO, brought deep expertise in AI and data science, while Dr. Pooja Rao, as the Head of R&D, provided the clinical and medical insight necessary to build clinically relevant tools.
The company’s growth trajectory has been fueled by strategic funding and investor confidence. Qure.ai has successfully raised significant capital to expand its R&D and global footprint. Most notably, in 2024, the company secured a Series D funding round of $65 million. This round was led by investors including Sequoia Capital India (now Peak XV Partners), MassMutual Ventures, Novo Holdings, and 360 One. This infusion of capital has allowed Qure.ai to aggressively expand into the US market while deepening its penetration in India, particularly in public health initiatives.
Regulatory approval acts as the gold standard for medical device safety and efficacy. Qure.ai distinguishes itself by being one of the few Indian health-tech companies to receive multiple clearances from the US Food and Drug Administration (FDA). Their flagship products, qXR and qER, have received FDA 510(k) clearance, validating their algorithms against rigorous standards. Additionally, Qure.ai holds the CE Mark for the European market and has received approvals and recommendations from the World Health Organization (WHO), particularly for its role in Tuberculosis screening. These regulatory milestones are not just badges of honor but prerequisites for large-scale deployment in clinical settings.
The company has garnered numerous accolades for its innovative approach. It has been recognized for its social impact, particularly for using technology to aid the underserved populations in India. From winning AI challenges to being featured in prestigious medical journals like The Lancet, Qure.ai has established scientific credibility alongside commercial success.
3. How Qure.ai Works – The Technology
At the heart of Qure.ai’s success lies its sophisticated Artificial Intelligence platform, built upon Deep Learning and Convolutional Neural Networks (CNNs). Unlike traditional computer vision which relies on manual feature extraction, deep learning algorithms “learn” directly from data. Qure.ai has trained its algorithms on a massive dataset of millions of medical images, curated from diverse demographic groups and pathologies. This diversity in training data ensures that the AI is robust and minimizes bias, a critical factor when deploying solutions across India’s varied population.
Core Product Lines
Qure.ai’s technology portfolio is centered around three main product lines, each targeting a specific diagnostic modality:
- qXR (Chest X-ray Analysis): This is perhaps the most widely deployed solution in India, given the ubiquity of X-rays. qXR is an automated chest X-ray interpretation tool that can detect multiple abnormalities in less than a minute. It is trained to identify 29 distinct findings, encompassing the lungs, pleura, heart, and diaphragm. Key capabilities include the detection of Tuberculosis (TB), lung nodules (indicative of cancer), pneumothorax (collapsed lung), and pleural effusion. In the context of the COVID-19 pandemic, qXR was retrained to identify ground-glass opacities typical of viral pneumonia, providing a crucial triage tool.
- qER (Head CT Scan Analysis): Designed for emergency settings, qER automates the interpretation of non-contrast head CT scans. It is FDA-cleared to detect critical abnormalities such as intracranial hemorrhage (bleeds), cranial fractures, mass effect, and midline shift. In stroke care, where “Time is Brain,” qER acts as a triage tool, prioritizing critical scans for the radiologist’s immediate attention. It can quantify the volume of a bleed and automate the calculation of the ASPECTS score, a metric used to assess the extent of ischemic stroke damage.
- qCT (Chest CT Analysis): This solution focuses on the chest CT modality, primarily for lung cancer screening and monitoring of lung diseases. It assists radiologists in detecting and characterizing lung nodules, tracking their growth over time, and assessing signs of emphysema or fibrosis.
Integration and Workflow: A key strength of Qure.ai’s technology is its seamless integration into existing hospital workflows. The AI does not require a separate interface; instead, it integrates directly with the Picture Archiving and Communication System (PACS) used by hospitals. The workflow is streamlined: when a patient undergoes a scan, the image is sent to the PACS server. Qure.ai’s algorithm processes the image in the background, typically taking less than 20 seconds. It then sends the annotated image and a preliminary report back to the radiologist’s workstation. This “pre-read” assistance highlights potential abnormalities, ensuring the radiologist doesn’t miss subtle findings and prioritizing urgent cases.
Accuracy Metrics: Clinical validation studies have demonstrated that Qure.ai’s algorithms perform at par with, and sometimes outperform, human radiologists. For tuberculosis screening, qXR has demonstrated sensitivity levels between 95-100% and specificity between 96-99% in various independent validation studies. Similarly, qER has shown high accuracy in detecting intracranial bleeds, significantly reducing the turnaround time for critical diagnoses.
4. Hospital Partnerships in India
Qure.ai’s impact in India is realized through strategic partnerships with both premier private hospital chains and public health bodies. These collaborations serve as the operational backbone for deploying AI at scale.
Medanta Hospital, Gurugram
In November 2021, Qure.ai announced a significant partnership with Medanta, one of India’s leading multi-specialty medical institutes. The collaboration involved deploying Qure.ai’s qXR solution across Medanta’s network of hospitals. Medanta, known for its high patient volume and complex cases, integrated the AI to serve as a second reader for chest X-rays. This deployment was not just about efficiency; it was about enhancing clinical safety. By automatically screening every chest X-ray for incidental findings—such as early-stage lung nodules that might be missed during a routine check-up for a different ailment—the AI helps in early disease detection and management.
Aster MIMS, Kozhikode
A pioneering example of AI in stroke care is the partnership with Aster MIMS (Malabar Institute of Medical Sciences) in Kozhikode, Kerala. Launched in March 2024 in collaboration with Medtronic India, this initiative established a Hub-and-Spoke model for stroke management. Aster MIMS serves as the “Hub,” equipped with advanced neuro-intervention capabilities, while smaller peripheral hospitals act as “Spokes.” Qure.ai’s qER solution is deployed at these spoke hospitals. When a patient presents with stroke symptoms at a peripheral center, the CT scan is analyzed by qER instantly. If a stroke is detected, the system alerts the neuro-intervention team at Aster MIMS immediately. This allows the specialists to evaluate the patient remotely and decide on transfer or treatment protocols minutes after the scan, significantly reducing the “door-to-needle” time.
Christian Medical College (CMC), Vellore
CMC Vellore, a heritage institution in Indian healthcare, has also integrated Qure.ai’s solutions into its workflow. As a tertiary care center managing a massive volume of patients from across the country, CMC utilizes AI to triage head CT scans in its busy emergency department. The implementation focuses on neurocritical care, ensuring that patients with traumatic brain injuries or strokes receive prioritized attention amidst the crowded casualty wards.
Municipal Corporation of Greater Mumbai (MCGM)
Perhaps the most impactful public sector deployment has been with the MCGM (Brihanmumbai Municipal Corporation). During the COVID-19 pandemic, Qure.ai deployed qXR across 15+ BMC sites, including major peripheral hospitals and dedicated COVID health centers. The AI was used to interpret chest X-rays for signs of COVID-19 pneumonia, acting as a proxy when RT-PCR tests were scarce or delayed. Beyond COVID, this infrastructure is now pivotal for the city’s Tuberculosis control program, screening over 45,000 scans to find “missing” TB cases in the slums of Mumbai.
5. Tuberculosis Detection in India
India bears the highest burden of tuberculosis (TB) globally, accounting for approximately 27% of all cases worldwide with 2.8 million incident cases annually. The Indian government has set an ambitious target to eliminate TB by 2025, five years ahead of the global SDG target. Achieving this requires finding the “missing millions”—patients who have TB but are undiagnosed or unreported. Qure.ai is a central technological pillar in this national endeavor.
The Challenge of Diagnosis: Traditional TB diagnosis relies on sputum microscopy (which has low sensitivity) or molecular tests like GeneXpert (which are expensive). Chest X-rays are a sensitive screening tool, but reading them requires radiologists, who are absent in rural Primary Health Centers (PHCs). Qure.ai’s qXR bridges this gap by reading X-rays automatically and flagging presumptive TB cases with a confidence score.
Case Study: MCGM Mumbai TB Program
The collaboration with the Municipal Corporation of Greater Mumbai (MCGM) showcases urban TB elimination in action. Launched in December 2020, this program integrated qXR into the workflow of municipal hospitals and mobile screening vans. From January 2021 to January 2022 alone, the system screened over 14,000 individuals.
The AI solution demonstrated the ability to detect 20-30% additional TB cases that were initially missed or asymptomatic. In a traditional setting, a patient might wait days for a radiologist’s report. With qXR, the report is generated in less than 3 minutes. This speed is vital for mobile vans serving slums like Dharavi; the patient can be triaged, counseled, and a sputum sample collected in a single visit, drastically reducing the “loss to follow-up” rate.
Case Study: STDC Nagpur Tribal Communities
In the tribal belts of Maharashtra, access to healthcare is further complicated by geography and infrastructure deficits. The State Tuberculosis Demonstration Centre (STDC) Nagpur launched the “X-rays on Wheels” initiative to reach these populations. However, the vans faced a bottleneck: no radiologists were available in these remote forests to read the scans.
In January 2023, the program integrated Qure.ai. The results were transformative. Across 16 tribal districts, the van screened 6,581 individuals. The AI flagged 730 abnormal chest X-rays, out of which 728 were identified as presumptive TB. Prior to AI integration, the turnaround time for a diagnosis—from X-ray to report to sputum collection—could take up to 1.5 months due to the logistics of sending films to the city. With Qure.ai, this cycle was reduced to one week, enabling rapid initiation of treatment for a vulnerable population.
6. Stroke Detection Cases
Stroke is a leading cause of death and disability in India, with an estimated 1.8 million cases annually. The treatment of ischemic stroke (caused by a clot) is strictly time-bound; thrombolysis or mechanical thrombectomy must be performed within a “golden window” of a few hours. “Time is Brain”—every minute of delay results in the death of nearly 2 million neurons.
The “Time is Brain” Imperative
In stroke care, every second counts. Qure.ai’s qER reduces the report turnaround time from hours to less than 2 minutes, directly impacting patient survival and recovery.
Aster MIMS Kozhikode Stroke Network: The Hub and Spoke model implemented here is a blueprint for stroke care in Tier-2 and Tier-3 India. Peripheral hospitals often lack full-time neurologists. When a patient arrives at a spoke hospital with stroke symptoms, a non-contrast CT is performed. qER processes this scan instantly. If it detects an intracranial hemorrhage, fracture, or signs of infarct, it sends an automated alert via a mobile app to the stroke team at the Aster MIMS Hub.
This automated notification system bypasses the traditional phone-tag communication chain. Neurologists at the Hub can view the AI-annotated images on their smartphones and advise the peripheral doctor to administer “clot-busting” drugs (thrombolytics) immediately or transfer the patient for surgery. This network has successfully managed hundreds of stroke codes, significantly improving functional outcomes for patients in the Malabar region.
Case Study: Rural India Stroke Patient
Consider the case of a patient at Aarthi Scans, a diagnostic chain with a presence in smaller towns. A 62-year-old woman presented late at night with slurred speech and weakness on one side of her body—classic stroke signs. The center did not have a radiologist on the night shift. However, the center was equipped with qER.
As soon as the CT scan was acquired, the AI analyzed the images. Within two minutes, it flagged a “Large Vessel Occlusion” and quantified the ASPECTS score. The system triggered a critical alert to the on-call radiologist and neurologist sleeping in a different city. woken by the alert, the specialist reviewed the AI’s findings on their mobile device, confirmed the diagnosis, and directed the center to transfer the patient immediately to a tertiary care center for a thrombectomy. The AI’s intervention saved hours of waiting time, preserving the “golden hour” and potentially saving the patient from permanent paralysis.
7. COVID-19 Response
The COVID-19 pandemic was a crucible for healthcare innovation, and Qure.ai stood at the forefront of India’s response. When the first wave hit in March 2020, testing kits (RT-PCR) were in critically short supply, and results took days. The medical community realized that COVID-19 pneumonia presented distinct patterns on chest X-rays, such as bilateral ground-glass opacities.
Qure.ai rapidly adapted its qXR algorithm to detect these specific patterns, creating a “COVID-19 score” indicating the likelihood of infection. In Mumbai, the epicenter of the outbreak in India, the MCGM deployed this solution across public hospitals and quarantine centers. Over 35,000 patients were screened using this AI tool. The AI helped triage patients: those with high likelihood scores on X-rays were isolated immediately, even while waiting for PCR results, preventing cross-infection in crowded waiting areas.
Furthermore, Qure.ai deployed qTrack, a disease progression monitoring tool. For hospitalized patients, qTrack quantified the percentage of lung affected by pneumonia over subsequent X-rays, helping doctors objectively decide when to escalate care (e.g., move to ICU) or when a patient was recovering enough for discharge. This technology was crucial in managing the overwhelming patient load during the Delta wave.
8. Lung Cancer Screening
Lung cancer is often diagnosed at a late stage in India, leading to poor survival rates. A significant opportunity lies in “Incidental Pulmonary Nodules” (IPNs)—small growths in the lungs detected accidentally during scans for other reasons (e.g., a chest X-ray for a pre-employment checkup or a CT scan for cardiac issues).
In May 2025, Qure.ai announced a landmark partnership with Johnson & Johnson MedTech to revolutionize lung cancer detection in India. The collaboration aims to establish IPN detection clinics across the country. The AI algorithms (qXR and qCT) serve as a safety net, automatically scanning every chest image for nodules. If a nodule is found, the system flags it for follow-up, ensuring the patient doesn’t slip through the cracks.
A precursor to this was a public health initiative in Goa, where AI screening was introduced in district hospitals. The system successfully identified several cases of early-stage lung cancer in asymptomatic individuals who were undergoing X-rays for general respiratory complaints. These patients were referred for biopsy and treatment at a stage where the cancer was still curable—a rarity in the Indian context.
9. Patient Success Stories
The Construction Worker in Mumbai: Ram (name changed), a 45-year-old migrant worker in Mumbai, attended a free health camp organized by an NGO. He had a persistent cough but dismissed it as a consequence of construction dust. The camp had a mobile X-ray van equipped with qXR. Within minutes of his scan, the AI flagged his X-ray with a high probability score for Tuberculosis and located a cavity in his upper right lung. The health workers immediately collected a sputum sample. Ram was diagnosed with TB and started on medication the same week. Without this AI-driven camp, Ram would likely have continued working, worsening his condition and infecting his fellow workers in the dormant barracks.
The Grandmother in Rural Maharashtra: 62-year-old Savitri Devi collapsed in her home in a village outside Nagpur. Her family rushed her to the nearest diagnostic center, fearing a heart attack. A CT scan was performed. The center had no radiologist on site at 2 AM. However, Qure.ai’s qER processed the scan and detected an acute ischemic stroke. The alert flashed on the console and notified the remote neurologist. The neurologist instructed the local duty doctor to administer care immediately and arrange transport. Savitri Devi reached the tertiary hospital within the treatment window. Today, she has regained 90% of her motor function—a recovery made possible because AI bridged the distance between her village and the specialist.
The Young Tech Professional: Ankit, a 28-year-old software engineer in Bangalore, underwent a master health checkup mandated by his company. He had no symptoms. The radiologist, overwhelmed with hundreds of healthy checkup scans, might have glanced over his chest X-ray quickly. But the qXR algorithm running in the background placed a bounding box around a tiny, faint nodule in the periphery of his left lung. This prompted the radiologist to take a second, closer look. A follow-up CT confirmed a small, early-stage malignant nodule. Ankit underwent minimally invasive surgery to remove it. He required no chemotherapy and is cancer-free today, saved by an algorithmic “second pair of eyes.”
Pediatric TB Detection: Diagnosing TB in children is notoriously difficult as they often cannot produce sputum, and their X-ray signs are subtle. Qure.ai became the first AI cleared to detect TB in children aged 0-3 years. In a pediatric ward in Delhi, a 2-year-old child presenting with failure to thrive and mild fever was screened. The AI detected enlarged lymph nodes in the chest—a subtle sign often missed. This finding guided the pediatricians to investigate for TB, leading to a confirmed diagnosis and life-saving treatment for the toddler.
10. Impact and Statistics
The scale of Qure.ai’s operations is a testament to the scalability of digital health solutions. From its Mumbai headquarters, the company’s footprint has expanded to over 100 countries. However, the depth of its impact is best understood through its Indian operations.
Key Impact Metrics
- Global Presence: Deployed in 3,000+ sites across 100+ countries.
- Scale: Processed over 5 million chest X-rays globally, with a significant portion in India.
- Efficiency: Studies show AI enables a radiologist to review up to 159 patients per day, compared to roughly 9-20 in a purely manual, detailed reporting workflow.
- Speed: AI analysis time is ~20 seconds versus 15-20 minutes for manual reporting and typing.
The economic impact is equally significant. By facilitating early detection of TB and lung cancer, the AI reduces the massive economic burden of treating advanced diseases. In stroke care, ensuring patients recover with minimal disability reduces the long-term costs of rehabilitation and lost productivity. The partnership with AstraZeneca alone aimed to screen millions, underscoring the shift from reactive medicine to proactive, population-scale screening.
11. Integration with Indian Healthcare System
Qure.ai does not operate in a silo; it is deeply entrenched in the Indian healthcare fabric. The company actively collaborates with the Central TB Division and is integrated into the National TB Elimination Program (NTEP) workflows in various states. Its solutions are compatible with the Ayushman Bharat Digital Mission (ABDM), India’s digital health backbone, ensuring that AI-generated reports can become part of a patient’s longitudinal health record.
Training is another critical component. Qure.ai runs programs to train technicians and radiologists on how to interpret AI outputs. It emphasizes that AI is a “Co-pilot,” not an autopilot. This approach has helped in gaining acceptance among the medical fraternity, moving the conversation from “AI vs. Doctors” to “AI + Doctors.”
12. Challenges and Solutions
Deploying high-tech AI in India is not without challenges. Infrastructure limitations in rural India, such as unstable internet connectivity, pose a hurdle for cloud-based AI. Qure.ai addressed this by developing offline capabilities. Their algorithms can run on a local server (an “edge” device) connected to the X-ray machine, requiring no internet to generate a report. This innovation was crucial for the deployment in tribal mobile vans.
Radiologist resistance was an initial barrier. To overcome this, Qure.ai positioned its tool as an efficiency multiplier rather than a replacement. By automating the mundane task of writing reports for normal scans and highlighting abnormalities in complex ones, they showed radiologists that AI reduces burnout.
Data privacy is paramount. Qure.ai adheres to strict data protection standards, including HIPAA and GDPR globally, and complies with India’s evolving digital data protection laws. All patient data is anonymized before processing, ensuring privacy is never compromised.
13. Future Outlook
The future of Qure.ai in India is expansive. The company is not resting on its laurels with X-rays and CTs. New models are in development for other modalities like ultrasound and MRI, which will open new frontiers in maternal health and musculoskeletal diagnostics. Predictive analytics is another frontier—moving from detecting “what is” to predicting “what will be,” such as estimating the risk of future cardiovascular events from chest X-rays.
Commercially, the company is on a path toward profitability and a potential IPO, driven by its scalable SaaS model. But the core vision remains impact-driven: to touch 1 billion lives. As India builds new AIIMS institutes and upgrades district hospitals, Qure.ai is poised to be the software layer that powers this hardware expansion, ensuring that quality diagnosis is a right, not a privilege, for every Indian.
14. Conclusion
Qure.ai represents the best of India’s “Make in India” ethos—a homegrown solution solving a global problem. By leveraging the power of artificial intelligence, it has fundamentally transformed diagnostic radiology in the country. It has bridged the yawning gap between the high-tech hospitals of Gurugram and the remote tribal hamlets of Gadchiroli. It has given the overworked radiologist a reliable assistant and the rural patient a fighting chance against time-critical diseases like stroke and TB.
In the grand tapestry of Indian healthcare, Qure.ai has woven a thread of efficiency, accuracy, and equity. As technology evolves, Qure.ai stands as a proof of concept that with the right innovation, the daunting challenges of healthcare accessibility can not only be met but overcome, saving lives one pixel at a time.